486. Vaccine effectiveness in preventing hospitalizations with influenza. Preliminary results from the Global Influenza Hospital Surveillance Network for the northern hemisphere 2013/14 influenza season using a test-negative approach
Session: Poster Abstract Session: Respiratory Infections: Influenza
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • IDWeek 486 GIHSN 13_14 IVE.ppt.pdf (1.7 MB)
  • Background:

    This was a multicentric study performed by the Global Influenza Hospital Surveillance Network (GIHSN). From December 2013 to June 2014 influenza-like-illness (ILI) admissions were prospectively screened for influenza viruses in 19 hospitals across Russia Federation; Turkey, China and Spain. Assessment of IVE evidence was facilitated by reducing the heterogeneity of evaluations across sites through the use of a common, standardized operational protocol.

    Methods:

    We followed the test negative-design to estimate IVE. A random effects logistic regression model was fitted with influenza RT-PCR results as the outcome and seasonal influenza vaccination status from registry records or recall data as the linear predictor. The I2test was used to asses heterogeneity between sites.

    Results:

    Of 4,660 eligible admissions, 1,018 (22%) were test positive patients (13% vaccinated) and 3,642 (78%) were test negative controls (20% vaccinated). Influenza A(H3N2) virus comprised a large proportion of test positive specimens. Moderate vaccine protection was observed overall, with adjusted effectiveness for the 2013/14 TIV against laboratory-confirmed influenza A(H3N2), A(H1N1) and B Yamagata lineage hospitalizations of 28%  (95%CI: -8 to 50), 38%, (95%CI 14 to 55) and 61%, (95%CI -3 to 86) respectively. By age, IVE estimates against A(H1N1) were significantly larger in the elderly than in younger patients (49% (95%CI 22 to 67) and 22% (95%CI -26 to 52) respectively). Statistical tests for heterogeneity by site were not significant.

    Conclusion:

    Influenza vaccine effectiveness in preventing admissions with influenza was low to moderate. While influenza vaccination is to be recommended for preventing influenza related disease, improved vaccines that offer better protection are needed.

    Joan Puig-Barberŕ, MD, MPH, PhD1, Angels Natividad-Sancho, PhD1, Svetlana Trushakova, MD PhD2, Anna Sominina, Prof.3, Elizaveta Smorodintseva, PhD3, Meral A.Ciblak, MD4, Selim Badur, Prof.4, Hongjie Yu, Dr. , MD, MPH5, Benjamin J.Cowling, BSc, PHD6, Ainara Mira-Iglesias, MSc.1, Lydumila Kolobukhina, MD2, Lubov Voloshchuk, MD3, Kubra Yurtcu, MSc.4, Peng Wu, PhD6 and Elena Burtseva, MD2, (1)Fundación para el Fomento de la investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain, (2)D.I. Ivanovsky Institute of Virology FGBC “N.F. Gamaleya FRCEM” Ministry of Health of Russian Federation, Moscow, Russia, (3)Research Institute of Influenza, Saint Petersburg, Russia, (4)National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, (5)Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China, (6)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

    Disclosures:

    J. Puig-Barberŕ, Sanofi Pasteur Institution: funding for the study , Research support

    A. Natividad-Sancho, Sanofi Pasteur Institution: funding for the study , Research support

    S. Trushakova, Sanofi Pasteur Institution: funding for the study , Research support

    A. Sominina, Sanofi Pasteur Institution: funding for the study , Research support

    E. Smorodintseva, Sanofi Pasteur Institution: funding for the study , Research support

    M. A.Ciblak, Sanofi Pasteur Institution: funding for the study , Research support

    S. Badur, Sanofi Pasteur Institution: funding for the study , Research support

    H. Yu, Sanofi Pasteur Institution: funding for the study , Research support

    B. J.Cowling, Sanofi Pasteur Institution: funding for the study , Research support

    A. Mira-Iglesias, Sanofi Pasteur Institution: funding for the study , Research support

    L. Kolobukhina, Sanofi Pasteur Institution: funding for the study , Research support

    L. Voloshchuk, Sanofi Pasteur Institution: funding for the study , Research support

    K. Yurtcu, Sanofi Pasteur Institution: funding for the study , Research support

    P. Wu, Sanofi Pasteur Institution: funding for the study , Research support

    E. Burtseva, Sanofi Pasteur Institution: funding for the study , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.